Skip to main content
SpringerLink
Log in

Mitochondrial Dysfunction in the Diabetic Kidney

  • Chapter
  • First Online:
Mitochondrial Dynamics in Cardiovascular Medicine

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 982))

Abstract

The role of mitochondria in diabetic complications has been viewed as a source of excess superoxide production leading to cell dysfunction. However, with the lack of benefit of non-specific anti-oxidant approaches this view needs to be re-evaluated. With recent studies using real-time imaging of superoxide, metabolomics, flux studies, transcriptomics and proteomics a new appreciation for the role of mitochondria in the evolution of diabetic kidney disease has emerged. Ongoing studies to further unravel the time course and mechanisms that reduce mitochondrial function will be relevant to novel therapies that could have a major impact on diabetic kidney disease and other diabetic complications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Filla LA, Edwards JL. Metabolomics in diabetic complications. Mol BioSyst. 2016;12:1090–105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Hallan S, Sharma K. The role of mitochondria in diabetic kidney disease. Curr Diabetes Rep. 2016;16:61.

    Article  Google Scholar 

  3. Darshi M, Van Espen B, Sharma K. Metabolomics in diabetic kidney disease: unraveling the biochemistry of a silent killer. Am J Nephrol. 2016;44:92–103.

    Article  CAS  PubMed  Google Scholar 

  4. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787–90.

    Article  CAS  PubMed  Google Scholar 

  5. Nishikawa T, Brownlee M, Araki E. Mitochondrial reactive oxygen species in the pathogenesis of early diabetic nephropathy. J Diabetes Investig. 2015;6:137–9.

    Article  CAS  PubMed  Google Scholar 

  6. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369:2492.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Alkhalaf A, Kleefstra N, Groenier KH, Bilo HJ, Gans RO, Heeringa P, et al. Effect of benfotiamine on advanced glycation end products and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One. 2012;7:e40427.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Dugan LL, You YH, Ali SS, Diamond-Stanic M, Miyamoto S, DeCleves AE, et al. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest. 2013;123:4888–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Coughlan MT, Nguyen TV, Penfold SA, Higgins GC, Thallas-Bonke V, Tan SM, et al. Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes. Clin Sci (Lond). 2016;130:711–20.

    Article  CAS  Google Scholar 

  10. Sharma K. Mitochondrial hormesis and diabetic complications. Diabetes. 2015;64:663–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Parikh SM, Yang Y, He L, Tang C, Zhan M, Dong Z. Mitochondrial function and disturbances in the septic kidney. Semin Nephrol. 2015;35:108–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Rosca MG, Vazquez EJ, Kerner J, Parland W, Chandler MP, Stanley W, et al. Cardiac mitochondria in heart failure: decrease in respirasomes and oxidative phosphorylation. Cardiovasc Res. 2008;80:30–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Santulli G, Xie W, Reiken SR, Marks AR. Mitochondrial calcium overload is a key determinant in heart failure. Proc Natl Acad Sci USA. 2015;112:11389–94.

    Google Scholar 

  14. Tran MT, Zsengeller ZK, Berg AH, Khankin EV, Bhasin MK, Kim W, et al. PGC1alpha drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature. 2016;531:528–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Solini A, Manca ML, Penno G, Pugliese G, Cobb JE, Ferrannini E. Prediction of declining renal function and albuminuria in patients with type 2 diabetes by metabolomics. J Clin Endocrinol Metab. 2016;101:696–704.

    Article  CAS  PubMed  Google Scholar 

  16. Niewczas MA, Sirich TL, Mathew AV, Skupien J, Mohney RP, Warram JH, et al. Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int. 2014;85:1214–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Atoh K, Itoh H, Haneda M. Serum indoxyl sulfate levels in patients with diabetic nephropathy: relation to renal function. Diabetes Res Clin Pract. 2009;83:220–6.

    Article  CAS  PubMed  Google Scholar 

  18. Rhee EP, Thadhani R. New insights into uremia-induced alterations in metabolic pathways. Curr Opin Nephrol Hypertens. 2011;20:593–8.

    Article  CAS  PubMed  Google Scholar 

  19. Makinen VP, Tynkkynen T, Soininen P, Forsblom C, Peltola T, Kangas AJ, et al. Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study). Metabolomics. 2012;8:369–75.

    Article  PubMed  Google Scholar 

  20. van der Kloet FM, Tempels FW, Ismail N, van der Heijden R, Kasper PT, Rojas-Cherto M, et al. Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics. 2012;8:109–19.

    Article  CAS  PubMed  Google Scholar 

  21. Sharma K, Karl B, Mathew AV, Gangoiti JA, Wassel CL, Saito R, et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol. 2013;24:1901–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Czajka A, Ajaz S, Gnudi L, Parsade CK, Jones P, Reid F, et al. Altered mitochondrial function, mitochondrial DNA and reduced metabolic flexibility in patients with diabetic nephropathy. EBioMedicine. 2015;2:499–512.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Tin A, Grams ME, Ashar FN, Lane JA, Rosenberg AZ, Grove ML, et al. Association between mitochondrial DNA copy number in peripheral blood and incident CKD in the atherosclerosis risk in communities study. J Am Soc Nephrol. 2016;27:2467–73.

    Article  CAS  PubMed  Google Scholar 

  24. Kang HM, Ahn SH, Choi P, Ko YA, Han SH, Chinga F, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2015;21:37–46.

    Article  CAS  PubMed  Google Scholar 

  25. Shaham O, Wei R, Wang TJ, Ricciardi C, Lewis GD, Vasan RS, et al. Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol. 2008;4:214.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002;51:2944–50.

    Article  CAS  PubMed  Google Scholar 

  27. Dobson AW, Kelley MR, Wilson GL, LeDoux SP. Targeting DNA repair proteins to mitochondria. Methods Mol Biol. 2002;197:351–62.

    CAS  PubMed  Google Scholar 

  28. Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong SE, et al. A mitochondrial protein compendium elucidates complex I disease biology. Cell. 2008;134:112–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Mustata GT, Rosca M, Biemel KM, Reihl O, Smith MA, Viswanathan A, et al. Paradoxical effects of green tea (Camellia sinensis) and antioxidant vitamins in diabetic rats: improved retinopathy and renal mitochondrial defects but deterioration of collagen matrix glycoxidation and cross-linking. Diabetes. 2005;54:517–26.

    Article  CAS  PubMed  Google Scholar 

  30. Wang W, Wang Y, Long J, Wang J, Haudek SB, Overbeek P, et al. Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. Cell Metab. 2012;15:186–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ayanga BA, Badal SS, Wang Y, Galvan DL, Chang BH, Schumacker PT, et al. Dynamin-related protein 1 deficiency improves mitochondrial fitness and protects against progression of diabetic nephropathy. J Am Soc Nephrol. 2016;27:2733–47.

    PubMed  Google Scholar 

  32. Xiao L, Zhu X, Yang S, Liu F, Zhou Z, Zhan M, et al. Rap1 ameliorates renal tubular injury in diabetic nephropathy. Diabetes. 2014;63:1366–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, et al. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 2005;3:e101.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Jang C, Oh SF, Wada S, Rowe GC, Liu L, Chan MC, et al. A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nat Med. 2016;22:421–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Tran M, Tam D, Bardia A, Bhasin M, Rowe GC, Kher A, et al. PGC-1alpha promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest. 2011;121:4003–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Hong YA, Lim JH, Kim MY, Kim TW, Kim Y, Yang KS, et al. Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1alpha in db/db mice. PLoS One. 2014;9:e96147.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Wu L, Wang Q, Guo F, Zhou Y, Ji H, Liu F, et al. Activation of FoxO1/PGC-1alpha prevents mitochondrial dysfunction and ameliorates mesangial cell injury in diabetic rats. Mol Cell Endocrinol. 2015;413:1–12.

    Article  CAS  PubMed  Google Scholar 

  38. Jeon SM. Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016;48:e245.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Eid AA, Ford BM, Block K, Kasinath BS, Gorin Y, Ghosh-Choudhury G, et al. AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes. J Biol Chem. 2010;285:37503–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, et al. A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol. 2007;292:F617–27.

    Article  CAS  PubMed  Google Scholar 

  41. Decleves AE, Mathew AV, Cunard R, Sharma K. AMPK mediates the initiation of kidney disease induced by a high-fat diet. J Am Soc Nephrol. 2011;22:1846–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Lee MJ, Feliers D, Sataranatarajan K, Mariappan MM, Li M, Barnes JL, et al. Resveratrol ameliorates high glucose-induced protein synthesis in glomerular epithelial cells. Cell Signal. 2010;22:65–70.

    Article  CAS  PubMed  Google Scholar 

  43. Han SH, Malaga-Dieguez L, Chinga F, Kang HM, Tao J, Reidy K, et al. Deletion of Lkb1 in renal tubular epithelial cells leads to CKD by altering metabolism. J Am Soc Nephrol. 2016;27:439–53.

    Article  CAS  PubMed  Google Scholar 

  44. Miyamoto S, Hsu CC, Hamm G, Darshi M, Diamond-Stanic M, Decleves AE, et al. Mass spectrometry imaging reveals elevated glomerular ATP/AMP in diabetes/obesity and identifies sphingomyelin as a possible mediator. EBioMedicine. 2016;7:121–34.

    Article  PubMed  PubMed Central  Google Scholar 

  45. You YH, Quach T, Saito R, Pham J, Sharma K. Metabolomics reveals a key role for fumarate in mediating the effects of NADPH oxidase 4 in diabetic kidney disease. J Am Soc Nephrol. 2016;27(2):466–81.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Metabolomic Medicine, Center for Renal Translational Medicine, University of California San Diego/Veterans Affairs San Diego Healthcare System, Stein Clinical Research Building, 4th Floor, 9500 Gilman Drive, La Jolla, CA, 92093-0711, USA

    Kumar Sharma

  2. Division of Nephrology-Hypertension, Veterans Affairs San Diego Healthcare System, La Jolla, CA, 92093, USA

    Kumar Sharma

Authors
  1. Kumar Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kumar Sharma .

Editor information

Editors and Affiliations

  1. Dept. of Biomedical Advanced Sciences, Federico II University, Naples, Italy

    Gaetano Santulli

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Sharma, K. (2017). Mitochondrial Dysfunction in the Diabetic Kidney. In: Santulli, G. (eds) Mitochondrial Dynamics in Cardiovascular Medicine. Advances in Experimental Medicine and Biology, vol 982. Springer, Cham. https://doi.org/10.1007/978-3-319-55330-6_28

Download citation

Publish with us

Policies and ethics

Search

Navigation